Supplementary Online Content

Meenan RT, Troja C, Buist DSM, et al. Economic evaluation of mailed home-based human papillomavirus self-sampling kits for cervical cancer screening. *JAMA Netw Open*. 2023;6(3):e234052. doi:10.1001/jamanetworkopen.2023.4052


eTable. Baseline Characteristics of Intervention and Control Group Participants
eFigure 1. Medicare-Based Cost-effectiveness Acceptability Curves by Screening History
eFigure 2. Medicare-Based Cost-effectiveness Acceptability Curves by Age Group


This supplemental material has been provided by the authors to give readers additional information about their work.


Characteristics ^a	Intervention (n =	Control (n =
	9843) ^b	9891)
Age at randomization, y		
30-34	808 (8.2)	794 (8.0)
35-39	932 (9.5)	915 (9.3)
40-44	1194 (12.1)	1185 (12.0)
45-49	1380 (14.0)	1374 (13.9)
50-54	1682 (17.1)	1707 (17.3)
55-59	1938 (19.7)	1943 (19.6)
60-64	1909 (19.4)	1973 (19.9)
Race ^c		
White	7018 (76.4)	7111 (77.1)
Asian	893 (9.7)	880 (9.5)
Black or African American	438 (4.8)	431 (4.7)
Native Hawaiian or other Pacific Islander	151 (1.6)	139 (1.5)
American Indian/Alaska Native	147 (1.6)	145 (1.6)
>1 Race	285 (3.1)	283 (3.1)
Other	250 (2.7)	235 (2.5)
Unknown	661 (6.7)	667 (6.7)
Ethnicity ^c		
Non-Hispanic	8710 (94.7)	8761 (94.8)
Hispanic	486 (5.3)	480 (5.2)
Unknown	647 (6.6)	650 (6.6)
Length of health plan enrollment, y		
3.4 to <5	2230 (22.7)	2240 (22.6)
5 to <10	3115 (31.6)	3045 (30.8)
≥10	4498 (45.7)	4606 (46.6)
Time since last Papanicolaou test (by length of		
enrollment), y		
Enrolled 3.4 to <5 y		
No.	2230	2240
No Papanicolaou test	1526 (68.4)	1530 (68.3)
>3.4 to <5	704 (31.6)	710 (31.7)
Enrolled 5 to <10 y		
No.	3115	3045
No Papanicolaou test	1056 (33.9)	1070 (35.1)
>3.4 to <5	1519 (48.8)	1468 (48.2)
5 to <10	540 (17.3)	507 (16.7)
Enrolled ≥10 y		
No.	4498	4606
No Papanicolaou test	694 (15.4)	666 (14.5)
>3.4 to <5	2186 (48.6)	2252 (48.9)
5 to <10	1143 (25.4)	1182 (25.7)
≥10	475 (10.6)	506 (11.0)

eTable. Baseline Characteristics of Intervention and Control Group Participants

Women's US Census block, median household	66 474 (50 343-	65 950 (50 536-	
income, median (IQR), \$	85 000)	83 949)	
Travel time from women's home to primary care			
clinic, min			
<10	3254 (33.4)	3236 (33.1)	
10 to <20	4086 (41.9)	4048 (41.4)	
20 to <30	1407 (14.4)	1415 (14.5)	
≥30	1004 (10.3)	1072 (11.0)	
Unknown	92 (0.9)	120 (1.2)	
Body mass index ^d			
<18.5	109 (1.3)	98 (1.2)	
18.5-24.9	2238 (26.5)	2248 (26.7)	
25-29.9	2168 (25.7)	2220 (26.3)	
30-34.9	1549 (18.4)	1603 (19.0)	
35-39.9	1119 (13.3)	1080 (12.8)	
≥40	1248 (14.8)	1184 (14.0)	
Unknown	1412 (14.3)	1458 (14.7)	
Tobacco use			
Never	5237 (61.2)	5232 (61.3)	
Current	1276 (14.9)	1290 (15.1)	
Former	2041 (23.9)	2020 (23.6)	
Unknown	1289 (13.1)	1349 (13.6)	
Charlson Comorbidity Index score ^e			
0	7967 (80.9)	8052 (81.4)	
1	1087 (11.0)	1128 (11.4)	
2	432 (4.4)	385 (3.9)	
≥3	357 (3.6)	326 (3.3)	
Randomization year			
2014	4207 (42.7)	4254 (43.0)	
2015	3570 (36.3)	3571 (36.1)	
2016	2066 (21.0)	2066 (20.9)	
Abbreviation: IQR, interquartile range.			
^a Based on electronic medical record (EMR) data.	·	·	
^b Baseline characteristics are not available for 117 part	ticipants who opted o	ut of EMR review.	
^c Race and ethnicity from EMR data per patient self-re	port at usual care pat	ient registration	
via preset multi-select categorical options, with "othe	r" allowing free text e	entry. The study	
variable was programmatically categorized into the di			
multiple selections as "more than one race". Manual of			
precluded because IRB approval did not allow individu	ual-level data for thos	e opting out of	
study participation.			
^d Calculated as weight in kilograms divided by height in meters squared.			
^e Charlson ME, Carrozzino D, Guidi J, Patierno C. Charlson Comorbidity Index: A critical review			
of clinimetric properties. Psychother Psychosom. 2022;91:8–35.			







eFigure 2. Medicare-Based Cost-effectiveness Acceptability Curves by Age Group